Cargando…
Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy
Triple negative breast cancer (TNBC) is marked by a lack of expression of the Estrogen Receptor, Progesterone Receptor, and human epidermal growth factor receptor 2. Therefore, targeted therapies are being investigated based on the expression profiles of tumors. Due to the potential for acquired and...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992589/ https://www.ncbi.nlm.nih.gov/pubmed/35582533 http://dx.doi.org/10.20517/cdr.2021.128 |